Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02799602
Title ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS)
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Bayer
Indications

prostate adenocarcinoma

Therapies

Darolutamide

Darolutamide + Docetaxel

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.